ANTX
Price
$1.26
Change
-$0.05 (-3.82%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
36.17M
76 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$9.55
Change
+$1.25 (+15.04%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
2.36B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANTX vs ERAS

Header iconANTX vs ERAS Comparison
Open Charts ANTX vs ERASBanner chart's image
AN2 Therapeutics
Price$1.26
Change-$0.05 (-3.82%)
Volume$1K
Capitalization36.17M
Erasca
Price$9.55
Change+$1.25 (+15.04%)
Volume$128.98K
Capitalization2.36B
ANTX vs ERAS Comparison Chart in %
ANTX
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ANTX vs. ERAS commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (ANTX: $1.31 vs. ERAS: $8.31)
Brand notoriety: ANTX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 120% vs. ERAS: 269%
Market capitalization -- ANTX: $36.17M vs. ERAS: $2.36B
ANTX [@Biotechnology] is valued at $36.17M. ERAS’s [@Biotechnology] market capitalization is $2.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 0 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than ANTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • ANTX’s TA Score: 5 bullish, 5 bearish.
  • ERAS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ANTX and ERAS are a good buy in the short-term.

Price Growth

ANTX (@Biotechnology) experienced а +19.09% price change this week, while ERAS (@Biotechnology) price change was +60.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

ANTX is expected to report earnings on Apr 01, 2026.

ERAS is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($2.36B) has a higher market cap than ANTX($36.2M). ERAS YTD gains are higher at: 123.387 vs. ANTX (14.912). ANTX has higher annual earnings (EBITDA): -37.4M vs. ERAS (-131.32M). ERAS has more cash in the bank: 288M vs. ANTX (61.9M). ANTX (0) and ERAS (0) have equivalent revenues.
ANTXERASANTX / ERAS
Capitalization36.2M2.36B2%
EBITDA-37.4M-131.32M28%
Gain YTD14.912123.38712%
P/E RatioN/AN/A-
Revenue00-
Total Cash61.9M288M21%
Total DebtN/A48.3M-
FUNDAMENTALS RATINGS
ANTX: Fundamental Ratings
ANTX
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
51
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
62

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ANTXERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ANTX
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JMSB19.810.32
+1.64%
John Marshall Bancorp
CRUS124.380.81
+0.66%
Cirrus Logic
BBVA24.47-0.20
-0.81%
Banco Bilbao Vizcaya Argentaria SA
PLTK3.63-0.04
-1.09%
Playtika Holding Corp
OTLK0.54-0.02
-3.81%
Outlook Therapeutics

ANTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with ELVN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
+3.97%
ELVN - ANTX
36%
Loosely correlated
+1.17%
ROIV - ANTX
33%
Loosely correlated
+1.58%
PASG - ANTX
32%
Poorly correlated
+6.24%
RNA - ANTX
29%
Poorly correlated
+0.15%
ERAS - ANTX
29%
Poorly correlated
+10.73%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+10.73%
RVMD - ERAS
61%
Loosely correlated
+1.06%
NUVL - ERAS
48%
Loosely correlated
+6.59%
ZNTL - ERAS
47%
Loosely correlated
+0.86%
CRNX - ERAS
47%
Loosely correlated
+2.04%
XNCR - ERAS
45%
Loosely correlated
+3.66%
More